Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27686017.
- Also identified by DOI 10.1146/annurev-med-052915-015720.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.
Medical subject headings
- Antiviral Agents
- HIV Infections
- Hepacivirus
- Hepatitis C